A&G Pharmaceutical and MedImmune Sign Collaboration and License Agreement for Oncology Research.Business Editors/Health & Medical Writers BIOWIRE2K BALTIMORE--(BW HealthWire)--April 24, 2002 A&G Pharmaceutical, Inc. is pleased to announce that it has signed a Collaboration and License Agreement with MedImmune, Inc. (NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on :MEDI MEDI Marine Environmental Data Information Referral System ) to develop and commercialize drugs based on A&G's research with PC cell-derived growth factor (PCDGF). "PCDGF is over-expressed in a majority of human advanced breast cancers. Inhibition of the action of PCDGF was shown to inhibit the tumor formation of breast cancer cells cells once believed to be peculiar to cancers, but now know to be epithelial cells differing in no respect from those found elsewhere in the body, and distinguished only by peculiarity of location and grouping. See also: Cancer . It is expected that antibodies to both PCDGF and its receptor will prevent the growth of and kill metastatic Metastatic The term used to describe a secondary cancer, or one that has spread from one area of the body to another. Mentioned in: Coagulation Disorders metastatic pertaining to or of the nature of a metastasis. breast cancer cells, thereby providing a powerful and specific therapeutic alternative to today's available treatments," stated Dr. Ginette Serrero, inventor of PCDGF technology and co-founder of A&G Pharmaceutical Inc. "The signing of this agreement with A&G reflects our ongoing commitment to building a world-class oncology business," stated Dr. Peter Kiener, MedImmune's Vice President of Research. "We look forward to working with A&G's management and scientific team to realize the exciting opportunity PCDGF offers for the potential treatment of cancer types." "To team up with MedImmune is a big endorsement of our technology," stated Le Sun, Ph.D., President of A&G Pharmaceutical. MedImmune will fund the PCDGF development efforts and will have sole responsibility for the commercialization of products resulting from this development effort. The companies will jointly manage strategic oversight and decision-making on all research and clinical development activities. A&G is also looking for Looking for In the context of general equities, this describing a buy interest in which a dealer is asked to offer stock, often involving a capital commitment. Antithesis of in touch with. corporate partner(s) to commercialize the diagnostic kit based on monoclonal anti-PCDGF antibody. As a part of the agreement, MedImmune made an equity investment in A&G and agreed to fund research activities related to PCDGF in exchange for an exclusive, worldwide license to therapeutic products directed against breast cancer. A&G received an up-front payment and will receive milestone payments and royalties based on global product sales. About MedImmune, Inc. MedImmune is a leading biotechnology company focused on researching, developing and commercializing products to prevent or treat infectious disease Infectious disease A pathological condition spread among biological species. Infectious diseases, although varied in their effects, are always associated with viruses, bacteria, fungi, protozoa, multicellular parasites and aberrant proteins known as prions. , autoimmune disease autoimmune disease, any of a number of abnormal conditions caused when the body produces antibodies to its own substances. In rheumatoid arthritis, a group of antibody molecules called collectively RF, or rheumatoid factor, is complexed to the individual's own gamma and cancer. MedImmune actively markets three therapeutic products and has 11 products in clinical testing. MedImmune employs approximately 1,500 people and is headquartered in Maryland. For more information, visit the company's website at www.medimmune.com. About A&G Pharmaceutical A&G Pharmaceutical Inc., a private biotechnology company based in Baltimore, MD, is becoming the preferred partner in drug discovery for Pharmaceutical and Biotech companies using its Monoclonal Antibody monoclonal antibody, an antibody that is mass produced in the laboratory from a single clone and that recognizes only one antigen. Monoclonal antibodies are typically made by fusing a normally short-lived, antibody-producing B cell (see immunity) to a fast-growing Development Service. The company also is aggressively developing monoclonal antibodies This is a list of monoclonal antibodies, antibodies which are clones of a single parent cell. When used as medications, the generic names end in -mab (see "Nomenclature of monoclonal antibodies"). to disease-specific surface antigens as therapeutic and diagnostic agents for various human diseases. For more information, visit company's website at www.agrx.net. http://www.agrx.net |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion